



Prevention and control of antimicrobial resistance in healthcare settings: raising awareness about best practices

Dominique L. Monnet, on behalf of ECDC Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Programme, ECDC Brussels, 22 November 2017 Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks



European Antimicrobial Resistance Surveillance Network (EARS-Net) (formerly EARSS, integrated in January 2010)

European Surveillance of Antimicrobial Consumption Network (ESAC-Net) (formerly ESAC, integrated in July 2011)

Healthcare-Associated Infections surveillance Network (HAI-Net) (formerly HELICS / IPSE, integrated in July 2008)

www.ecdc.europa.eu

Staphylococcus aureus: % of invasive isolates with resistance to meticillin (MRSA), EU/EEA, 2013 & 2016





Source: EARS-Net, 2017. The symbols ↑ and ↓ indicate a significant increasing or decreasing trend for the period 2013-2016, respectively. These trends were calculated on laboratories that consistently reported during this period.

Klebsiella pneumoniae: % of invasive isolates with <u>combined resistance</u>* EU/EEA, 2013 & 2016

2013

*Third-generation cephalosporins, fluoroquinolones and aminoglycosides

2016



Klebsiella pneumoniae: % of invasive isolates with <u>resistance to carbapenems</u> EU/EEA, 2013 & 2016





Source: EARS-Net, 2017. The symbols ↑ and ↓ indicate a significant increasing or decreasing trend for the period 2013-2016, respectively. These trends were calculated on laboratories that consistently reported during this period.

Carbapenem-resistant infections: a challenge for appropriate patient therapy



1. Klebsiella pneumoniae ESBL-CARBA > E5 CFU/mL MIC: Aztreonam = 0.25 mg/L = S MIC: Colistin = 0.12 mg/L = S MIC: Kloramfenikol = 256 mg/L = RMIC: Tobramycin = <256 mg/L = R MIC: Amikacin = <256 mg/L = R MIC: Netilmicin = <256 mg/L = R MIC: Nitrofurantoin = 512 mg/L = R MIC: Gentamicin = <256 mg/L = R Obs! Stammen bildar ESBL-CARBA (ICD-10 kod U82.2), Klinisk anmälningsplikt och smittspårningsplikt enl smittskyddslagen. Kontakta alltid vårdhygien. För mer information: www.smittskyddstockholm.se

ANTIBIOTIKUM

Ampicillin	R
Piperacillin/tazobaktam.	R
Cefadroxil	R
Imipenem	R
Meropenem	R
Ertapenem	R
Aztreonam	S
Colistin	S
Kloramfenikol	R
Tobramycin	R
Amikacin	R
Netilmicin	R
Trimetoprim	R
Trimetoprim-sulfa	R
Nitrofurantoin	R
Cefotaxim	R
Ceftazidim	R
Gentamicin	R
Ciprofloxacin	R
	-

Svarskommentar: Sammanfattning/Övrigt:

Obs! Mycket omfattande resistensprofil, Endast känslig för colistin.

Courtesy: C. Giske. Karolinska University Hospital, Stockholm, Swede.n Photo: www.microbiologie.info.

ECDC point prevalence survey, 2011-2012: antimicrobial use in European acute care hospitals

- On any given day: 33% patients [range: 21-55%]
- 59% of surgical prophylaxis > 1 day



1 Day >1 Day

Source: ECDC report, July 2013.

Consumption of last-line antibiotics in the hospital sector, EU/EEA, 2012-2016

Carbapenems

(DDD per 1000 inh. and per day)



Polymyxins (mainly colistin)

(DDD per 1000 inh. and per day)

Country	2016	Trends in consumption of polymyzins, 2012–2016
Finland (a)	0	
Lithuania	0	
Norway	0.001	
Sweden	0.001	
Latvia	0.002	
Netherlands	0.002	
Bulgaria	0.004	
Estonia	0.005	~
Luxembourg	0.005	
Denmark	0.006	1
Ireland	0.006	in the second
United Kingdom	0.006	
France	0.007	
Belgium	0.008	The
Slovenia	0.008	
Hungary	0.010	
EU/EEA	0.016	~
Malta	0.016	
Croatia	0.017	~
Cyprus	0.019*	1
Portugal (b)	0.022	~
Romania	0.026*	
Italy	0.027	
Poland	0.034	-
Slovakia	0.035	m
Greece	0.102	



- * Cyprus and Romania: total care data, including consumption in the community. These data were not used to calculate the EU/EEA populationweighted average.
- (a) Finland: data include consumption in remote primary healthcare centres and nursing homes.
- (b) Portugal: data relate to public hospitals only.

Source: ESAC-Net, 2017. The symbols \uparrow and \checkmark indicate a significant increasing or decreasing trend for the period 2012-2016, respectively.

Klebsiella pneumoniae: % of invasive isolates with combined resistance to <u>carbapenems and colistin</u>, EU/EEA, 2016







Source: EARS-Net, 2017

All isolates tested for carbapenem susceptibility were included in the denominator to limit the effect of sequential testing.



European Centre for Disease Prevention and Control

An agency of the European Union

M Infectious diseases & public health

ECDC

News & events Publications & data About us Q

Home > Publications & data > Epidemic Intelligence Information System (EPIS)

Publications & data

Examples

- Mycobacterium chimaera cardiovascular infections linked to heater-cooler devices
- Candida auris infection
- optrA (transferable oxazolidinone and chloramphenicol resistance)

Epidemic Intelligence Information System (EPIS)

tool



The Epidemic Intelligence Information System (EPIS) is a web-based communication platform that allows nominated public health experts to exchange technical information to assess whether current and emerging public health threats have a potential impact in the European Union (EU).

Download

LEPIS - specific privacy statement - 2016 - EN - [PDF-106.53 KB]



Main actions to prevent and control antimicrobial resistance (AMR)





New antimicrobial agents (with a novel mechanism of action, research, development)



Infection prevention and control (hand hygiene, screening, isolation)



Prudent use of antimicrobial agents (only when needed, correct dose, correct dose intervals, correct duration)

EU Guidelines for the prudent use of antimicrobials in human health (June 2017)





https://ec.europa.eu/health/amr/action eu en



Publications & data

Directory of online resources for prevention and control of antimicrobial resistance (AMR) and healthcare-associated infections (HAI)

loar

🛩 f in 🖂

The directory lists strategies, guidance documents and training courses on the prevention and control of antimicrobial resistance and healthcare-associated infections available online. These documents were published by ECDC, EU/EEA Member States, international and national agencies and professional societies to support healthcare professionals, hospital administrators and public health professionals. In addition, the directory lists ongoing research projects and their corresponding websites.

ECDC welcomes suggestions and further information on existing guidance. Comments can be provided to: arhai@ecdc.europa.eu.

Guidelines for specific infections and organisms



Update : **15 Nov. 2017**



Antimicrobial resistance strategies and action plans

Projects on antimicrobial resistance and healthcare-associated infections

https://ecdc.europa.eu/en/publications-data/directory-online-resources-prevention-and-control-antimicrobial-resistance-amr

Control of an outbreak of OXA-48producing *Enterobacteriaceae*, Maastad Hosp., Rotterdam (NL), 2009-2012



Source: Dautzenberg MJ, et al. Eurosurveillance (6 March 2014).

Carbapenemase-producing *Enterobacteriaceae*: long-term control of hospital outbreaks in Paris, France, 2004-2012





A CPE event was defined as one index case (respectively defined as infected or colonised with CPE), followed or not by secondary case(s).

Source: Fournier S, et al. Eurosurveillance (15 May 2014).

Infection prevention and control measures and tools to prevent entry of carbapenem-resistant *Enterobacteriaceae* (CRE) into healthcare settings: ECDC guidance



Core measures

- Profile for <u>"at risk" patients</u> who require supplemental measures
- Preliminary supplemental measures (at admission, for "at risk" patients)
- **Supplemental measures** (for confirmed CRE-positive patients)



Source: Magiorakos et al. Antimicrob Resist Infect Control (15 November 2017).

Antimicrobial consumption drives antimicrobial resistance in hospitals





Source: Lepper PM, et al. Antimicrob Agents Chemother 2002 Sep;46(9):2920-5.

Intervention to control carbapenem-resistant *Klebsiella pneumoniae*, onco-haematology unit, Greece, 2011-2014



Total Antibiotic consumpion

Source: AMR Next, 2016. https://www.government.nl/documents/leaflets/2016/04/18/factsheet-eu-antimicrobial-resistance-one-health-ministerial-conference-2016

Example of national initiative on surgical prophylaxis, Belgium, 1997



- Royal Decree: reimbursement of prophylactic antibiotics by surgical procedure, 1997
- Prophylaxis given when indicated: from 92.3% (1992-1996) to 95.3% (1998-1999)
- Prolonged administration: from 19.8% to 9.9%
- Use of more than one antibiotic per procedure: from 16.3% to 5.5%



Source: Carsauw H, et al. ICHE 2000; 21: 89 & Goossens H, et al. 40th ICAAC, 2000, abstr. O-111.



EUROPEAN ANTIBIOTIC AWARENESS DAY

A EUROPEAN HEALTH INITIATIVE

Plan a campaign For healthcare workers Get informed Get involved Campaigns in Europe

English (en) -

News About Q

Communicating to professionals in hospitals and long-term care facilities

Up to half of all antibiotic use in hospitals is unnecessary of inappropriate. Antibiotic misuse in hospitals is a major driver of antibiotics resistance. What can be done?

View materials

New communication toolkit

Patient stories

Data and reports



#KeepAntibioticsWorking: join us on social media!

As a healthcare professional, what can you do to keep antibiotics working? What can a patient association do to contribute? What can policymakers do at European level? What can a parent do? Everyone can join the campaign on European Antibiotics Awareness Day-posting his/her own message, picture or video using the #KeepAntibioticsWorking hashtag. Tell the world what you do, in your professional or personal life, at individual or collective level, to use antibiotics responsibly and #KeepAntibioticsWorking!

Read about the #KeepAntibioticsWorking campaign



Home > For healthcare workers > Materials for professionals in hospitals and other healthcare settings

K For healthcare workers

Materials for primary care prescribers

Materials for professionals in hospitals and other healthcare settings

Materials for professionals in hospitals and other healthcare settings



Materials for professionals in hospitals and other healthcare settings, such as long-term care facilities, who have different roles and influence in the use of antibiotics in such settings.



New EAAD toolkit (1)



• Objective

- to support efforts to increase prudent use of antibiotics in hospitals and other healthcare settings through dissemination of evidence-based educational and information materials.

- Review of the scientific literature by ECDC experts ("evidence-based", 111 references) and extensive consultation and editing process.
- Some of the messages are indicated to be "expert consensus": agreement reached by ECDC experts, EAAD Technical Advisory Committee members, and other external experts and stakeholders.

New EAAD toolkit (2)



Key messages

- Primary target audience: professionals in hospitals and other healthcare settings, who have different roles and influence in the use of antibiotics in such settings:
 - Managers/administrators,
 - Infectious disease specialists,
 - Infection prevention and control professionals,
 - Epidemiologists,
 - Prescribers,
 - Junior doctors and students,
 - Pharmacists,
 - Nurses,
 - Clinical microbiologists,
 - Professionals in emergency departments,
 - Professionals in intensive care units,
 - Professionals in long-term care facilities



Home > Get informed > Key messages > Key messages for professionals in hospitals and other healthcare settings > Hospital managers / administrators

 Key messages for professionals in hospitals and other healthcare settings

All prescribers

Healthcare professionals in hospitals and other healthcare settings

Hospital infectious disease specialists

Hospital managers / administrators

Infection prevention and control professionals and hospital epidemiologists

Key messages for hospital

Key messages for hospital managers / administrators

У f in 🖂

Tasks

1. Your tasks related to improving antibiotic use include [31,42,56,71,75]:

a) Establishing a multidisciplinary team for your hospital antibiotic stewardship programme. This team should include infectious disease specialists, clinical microbiologists and pharmacists, and should receive dedicated funding and resources;

b) Supporting implementation of antibiotic guidelines and infection prevention and control measures;

c) Implementing targeted educational activities and training that:

i. optimise the diagnostic and therapeutic management of patients;

Things you should know

Things you can do in your hospital or institution

New EAAD materials



- Aim at creating a sense of individual responsibility in tackling antibiotic resistance and at empowering professionals to take action.
- Include one slogan, linking all materials:
 "Antibiotics: handle with care".
- Available in Adobe InDesign, Microsoft Word and Microsoft PowerPoint, which makes it easy to adapt them by anyone with experience in any of these three software packages.
- Need to be adapted to national contexts to better respond to specific communication needs.

Antibiotics: handle with care!



Our hospital

Up to half of all antibiotic use Antibiotics: in hospitals is unnecessary or handle with care! inappropriate

As a hospital prescriber, you have a responsibility to use ant and to ensure that they remain effective. In your role, you mu



Follow infection prevention and control guidance;

Initiate antibiotic treatment as soon as possible in patients with severe infection;



Ensure that relevant cultures are taken timely;

Re-evaluate treatment after 48-72 hours, or when results from microbiological samples are available



Prescribe according to evidence-based hospital antibio



for common infections and for surgical prophylaxis;



Inform your patients of any antibiotics prescribed, and their potential adverse effects.





Antibiotic resistance keeps increasing Antibiotics: in Europe, threatening patient safety handle with care! in all healthcare settings

Nurses

As a nurse, you have a responsibility to use antibiotic prudently ensure that they remain effective. In your role, you must:



Hospital prescribers

Follow infection prevention and control guidance



Administer antibiotics to patients according to the prescription



Coordinate the taking and sending of microbiological specimen and their reporting back to physicians

Report adverse effects of antibiotic therapy to physicians and to appropriate review committees

Manage antibiotic stocks on your ward, and ensuring the tracea of antibiotic use

Provide information on treatments to patients and families





In this hospital we are committed to use antibiotics prudently and to ensure that they remain effective



100

We follow infection prevention and control guidance;

We initiate antibiotic treatment as soon as possible in patients with severe infection;



We re-evaluate treatment after 48-72 hours, or when results from microbiological samples are available;

We prescribe according to evidence-based hospital antibiotic guidelines for common infections and for surgical prophylaxis;



We inform our patients of any antibiotics prescribed, and their potential adverse effects.



All the statements in this power are supported by scientific





Careful as the Research and the second system is the proof of the party terms in the second sec

tion when have been all the set of the set o

Construction of the second sec

appliants and applicate local publication of the second states in the

the designers with the second second second second periodic of printer providence of silvers in special of

the same in the local state is strategic in the same state in

the local name







Antibiotic resistance: You are responsible to ensure that antibiotics remain effective

This checklist is supported by scientific esidence. Visit http://antibutit.ecdc. exclude any or nears the QR code.





the second schedule of the second schedule of

1. Control on Age 1 and place spectra and a second spectra of a second secon When the address and a second se

NAME OF TAXABLE PARTY AND ADDRESS OF TAXABLE PARTY. States and

the Artist statistic procession of

Name of a laboration of a supervision of a state of the supervision of the first design and the second processing in the terminal particular in the second state of the and the second se and the experimental part of the state in the second second second second

When have a same range of any installed as when done of



- is there a high probability of a bacterial infection, С
- rather than colonization or a viral infection?
- Does the patient have an infection that will respond C to antibiotics?

Have you checked the patient's recent antibiotic use, drug allergies, hospitalisation or institutionalisation, 0

- use of immunosuppressive therapy and microbiology results for the previous 3 months?
- is the patient on the right antibiotics, dosage, and route of administration?
- Can an antibiotic with a narrower spectrum be used С to treat the infection?
- Have you prescribed the shortest possible duration 0 of treatment?
- 0 Have the appropriate cultures been taken?
- Do the culture results necessitate starting antibiotic therapy or modifying ongoing the current antibiotic.
- therapy? Have you documented the indication of antibiotic.
- treatment, drug choice, dosage, route of administration and duration of treatment in the
- patient chart? Does the choice of antibiotic therapy comply with
- 0 your hospital's guidelines?
- Does the choice of antibiotic therapy comply with your hospital's antibiotic resistance patterns?

If you have doubts, connait (antibiatic viewanitably programme, recobiologist, infectious disance specialist; in our hospital, Cannect jemail address] or call [phane number]. See more toformation at ital website/6AAD website(



Leaflets



Checklists



- Burden of antimicrobial resistance (AMR) for the EU/EEA (Q2 2018)
- Annual update on AMR and antimicrobial consumption in humans in the EU/EEA (November 2018)
- ECDC point prevalence surveys of HAIs, AMR and antimicrobial use in European acute care hospitals and in long-term care facilities, 2016-2017 (ECDC publications, November 2018)
- Contribution to the implementation of the European
 One Health Action Plan against Antimicrobial
 Resistance (AMR)

Thank you!

EUROPEAN ANTIBIOTIC AWARENESS DAY



A EUROPEAN HEALTH INITIATIVE

18 November 2017

EU event, Brussels, 15 November 2017

E-mail: Website: Facebook: Twitter: Global Twitter:

EAAD@ecdc.europa.eu https://antibiotic.ecdc.europa.eu EAAD.EU @EAAD_EU (#EAAD) #AntibioticResistance



WORLD ANTIBIOTIC AWARENESS WEEK

